Abel Hall LLC’s aTyr Pharma ATYR Stock Holding History

Abel Hall LLC’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-553	Closed	-$13.2K	–	1054
2026 Q2	$13.2K	Buy	+553	New	+$14.4K	﹤0.01%	949

Other funds holding ATYR

Kingswood Wealth Advisors San Diego, California $2.6B AUM 27.46% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Ares Financial Consulting Calabasas, California $145M AUM 16.02% 1-Year Est. Return

Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return

Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

SJS Investment Consulting Sylvania, Ohio $993M AUM 16.29% 1-Year Est. Return

Abel Hall LLC's ATYR Position: Q3 2026 in Review

Abel Hall LLC sold out of aTyr Pharma (ATYR) in Q3 2026, closing a stake of 553 shares — an estimated $13.2K sold.

Abel Hall LLC first reported a position in ATYR in Q2 2026 and held it in 1 quarter. The position peaked at $13.2K in Q2 2026. 10 funds tracked by Wall St. Rank hold ATYR as of Q3 2026.

Abel Hall LLC reported no remaining aTyr Pharma position as of Q3 2026 after selling out during the quarter.
Abel Hall LLC sold 553 aTyr Pharma shares in Q3 2026, an estimated $13.2K.
Abel Hall LLC first reported a position in aTyr Pharma in Q2 2026 and held it in 1 quarter.
Abel Hall LLC's aTyr Pharma position peaked at $13.2K in Q2 2026.
10 funds tracked by Wall St. Rank held aTyr Pharma as of Q3 2026.

Based on Abel Hall LLC's 13F filing for Q3 2026, filed 19 Oct 2026.